ArticleBioMed research international2022
Emergence of High Prevalence of Extended-Spectrum Beta-Lactamase and Carbapenemase-Producing
Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Prevalence of carbapenemase-producing Enterobacteriaceae from human clinical samples in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Extended spectrum beta lactamases and carbapenemase-producingOne health (Amsterdam, Netherlands) · 2026Review
- Characterization of novel phage Henuyfy11N: a potential therapeutic agent against extended-spectrum β-lactamase (ESBL)-producingMicrobiology spectrum · 2026Article
- Molecular characterization of IMP and NDM resistance genes in carbapenemase-producing Enterobacteriaceae isolates in urine.Molecular biology reports · 2026Article
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Klebsiella pneumoniae in humans, animals and the environment in Northwest Amhara, Ethiopia.Scientific reports · 2026Article
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Escherichia coli from patients, cattle, and environmental sources in northwest Amhara, Ethiopia: a one health approach.BMC microbiology · 2026Article
- Prevalence of wound infections and related antimicrobial resistance in Goma, Democratic Republic of the Congo: a multicenter cross-sectional study.BMC infectious diseases · 2026Article
- Article
- Prevalence, multidrug resistance patterns, and carbapenemase-encoding genes of carbapenemase-producingSAGE open medicine · 2026Review
- High Prevalence of Multidrug-Resistant Bacterial Colonization Among Patients and Healthcare Workers in a Rural Ethiopian Hospital.Antibiotics (Basel, Switzerland) · 2025Article
- The magnitude of MDR carbapenemase-producing Enterobacteriaceae isolates and associated factors among hospitalized patients of Northeast Ethiopia.JAC-antimicrobial resistance · 2025Article
- Genotypic Characterisation and Antimicrobial Resistance of Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial resistance profile and associated factors of hospital-acquired gram-negative bacterial pathogens among hospitalized patients in northeast Ethiopia.BMC microbiology · 2024Article
- The Importance of Carbapenemase-Producing Enterobacterales in African Countries: Evolution and Current Burden.Antibiotics (Basel, Switzerland) · 2024Review
- Incidence of catheter-associated urinary tract infections by Gram-negative bacilli and their ESBL and carbapenemase production in specialized hospitals of Bahir Dar, northwest Ethiopia.Antimicrobial resistance and infection control · 2024Article
- Evaluation of Acinetobacter baumannii, Klebsiella pneumoniae, and Staphylococcus aureus respiratory tract superinfections among patients with COVID-19 at a tertiary-care hospital in Tehran, Iran.European journal of medical research · 2023Article
- Antimicrobial Resistance Patterns and Risk Factors Associated with ESBL-Producing and MDRMicroorganisms · 2023Article
- Prevalence of Carbapenemase and Extended-Spectrum β-Lactamase ProducingAntibiotics (Basel, Switzerland) · 2023Article
- A brief insight intoFrontiers in antibiotics · 2023Review
- Distribution of ß-Lactamase Genes Among Multidrug-Resistant and Extended-Spectrum ß-Lactamase-Producing DiarrheagenicInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWorld Health Organization identified some MATERIALS AND
methodsA hospital-based cross-sectional study was carried out from February to April 2019 in the Northwestern Ethiopia region. A total of 384 patients presumptive for bacterial infections were conveniently enrolled in the study. Specimens were collected and processed following standard bacteriological procedures. Drug susceptibility tests were performed using disk diffusion technique. ESBL and carbapenemase enzymes were tested by double disk diffusion and modified carbapenem inhibition methods, respectively. The data obtained were analyzed using SPSS version 22 software, and descriptive statistics were summarized in tables and graphs.
resultsOut of 384 clinical specimens processed 100 (26%) were culture positive for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.